272 related articles for article (PubMed ID: 34563918)
1. IgG regulation through FcRn blocking: A novel mechanism for the treatment of myasthenia gravis.
Wolfe GI; Ward ES; de Haard H; Ulrichts P; Mozaffar T; Pasnoor M; Vidarsson G
J Neurol Sci; 2021 Nov; 430():118074. PubMed ID: 34563918
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis.
Sivadasan A; Bril V
Immunotherapy; 2023 Jun; 15(8):553-563. PubMed ID: 37013835
[TBL] [Abstract][Full Text] [Related]
3. Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis.
Gable KL; Guptill JT
Front Immunol; 2019; 10():3052. PubMed ID: 31998320
[TBL] [Abstract][Full Text] [Related]
4. [Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease].
Murai H; Harada D
Brain Nerve; 2024 Feb; 76(2):183-191. PubMed ID: 38351566
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
6. Neonatal Fc Receptor Inhibitor Therapeutics in Neuromuscular Disease.
Jaffry M; Menkes DL; Shaikh A; Mandava K; Kothari O; Jaffry K; Souayah N
J Clin Neuromuscul Dis; 2023 Jun; 24(4):188-198. PubMed ID: 37219862
[TBL] [Abstract][Full Text] [Related]
7. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
Patel DD; Bussel JB
J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
[TBL] [Abstract][Full Text] [Related]
8. FcRN receptor antagonists in the management of myasthenia gravis.
Bhandari V; Bril V
Front Neurol; 2023; 14():1229112. PubMed ID: 37602255
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
[TBL] [Abstract][Full Text] [Related]
10. Neonatal Fc Receptor-Targeted Therapies in Neurology.
Nelke C; Spatola M; Schroeter CB; Wiendl H; Lünemann JD
Neurotherapeutics; 2022 Apr; 19(3):729-740. PubMed ID: 34997443
[TBL] [Abstract][Full Text] [Related]
11. Fc-Receptor Targeted Therapies for the Treatment of
Keller CW; Pawlitzki M; Wiendl H; Lünemann JD
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071155
[No Abstract] [Full Text] [Related]
12. Effect of FcRn antagonism on protective antibodies and to vaccines in IgG-mediated autoimmune diseases pemphigus and generalised myasthenia gravis.
Guptill JT; Sleasman JW; Steeland S; Sips M; Gelinas D; de Haard H; Azar A; Winthrop KL
Autoimmunity; 2022 Dec; 55(8):620-631. PubMed ID: 36036539
[TBL] [Abstract][Full Text] [Related]
13. FcRn inhibitors: a novel option for the treatment of myasthenia gravis.
Zhu LN; Hou HM; Wang S; Zhang S; Wang GG; Guo ZY; Wu J
Neural Regen Res; 2023 Aug; 18(8):1637-1644. PubMed ID: 36751773
[TBL] [Abstract][Full Text] [Related]
14. Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
Di Stefano V; Alonge P; Rini N; Militello M; Lupica A; Torrente A; Brighina F
J Neurol; 2024 Jan; 271(1):254-262. PubMed ID: 37682316
[TBL] [Abstract][Full Text] [Related]
15. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.
Li N; Zhao M; Hilario-Vargas J; Prisayanh P; Warren S; Diaz LA; Roopenian DC; Liu Z
J Clin Invest; 2005 Dec; 115(12):3440-50. PubMed ID: 16284651
[TBL] [Abstract][Full Text] [Related]
16. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
[TBL] [Abstract][Full Text] [Related]
17. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.
Peter HH; Ochs HD; Cunningham-Rundles C; Vinh DC; Kiessling P; Greve B; Jolles S
J Allergy Clin Immunol; 2020 Sep; 146(3):479-491.e5. PubMed ID: 32896308
[TBL] [Abstract][Full Text] [Related]
18. Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center.
Frangiamore R; Rinaldi E; Vanoli F; Andreetta F; Ciusani E; Bonanno S; Maggi L; Gallone A; Colasuonno A; Tramacere I; Cheli M; Pinna A; Mantegazza R; Antozzi C
Eur J Neurol; 2024 Apr; 31(4):e16189. PubMed ID: 38164996
[TBL] [Abstract][Full Text] [Related]
19. FcRn Inhibitor Therapies in Neurologic Diseases.
Alfaidi N; Karmastaji S; Matic A; Bril V
CNS Drugs; 2024 Jun; 38(6):425-441. PubMed ID: 38724842
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade.
Liu L; Garcia AM; Santoro H; Zhang Y; McDonnell K; Dumont J; Bitonti A
J Immunol; 2007 Apr; 178(8):5390-8. PubMed ID: 17404325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]